Umedaptanib Pegol is under clinical development by Ribomic and currently in Phase II for Wet (Neovascular / Exudative) Macular Degeneration. According to GlobalData, Phase II drugs for Wet (Neovascular / Exudative) Macular Degeneration have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Umedaptanib Pegol’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Umedaptanib Pegol overview

Umedaptanib pegol is under development for the treatment of achondroplasia, cancer pain and exudative choroidal neovascularization age-related macular degeneration (AMD). The drug candidate is an aptamer which acts by targeting fibroblast growth factor 2. It is based on ribomic aptamer refined therapeutics system (RiboART) and systematic evolution of ligands by exponential enrichment (SELEX) technology. It is administered through the intravitreal and subcutaneous route.

It was under development for lung cancer, osteoporosis, arthritis, bone diseases, idiopathic pulmonary fibrosis and other organ fibrosis.

Ribomic overview

Ribomic, a subsidiary of Otsuka Pharmaceutical Co Ltd, is a biopharmaceutical venture company. It develops molecular targeted pharmaceutical drugs using RNA aptamers. The company’s technology includes RiboART system a platform technology to treat therapeutic aptamers. Ribomic’s pipeline products include RBM001, RBM011, RBM010, RBM003, RBM004, RBM006, RBM007 and RBM008. The company’s products are used to treat pain, sepsis, lung fibrosis and other organ fibrosis, bone diseases and eye diseases and inflammatory disorders. It has collaboration with other pharmaceutical companies for research and development activities. Ribomic is headquartered in Minato Ku, Tokyo, Japan.

For a complete picture of Umedaptanib Pegol’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.